WASHINGTON (AP) — A new strategy to fight an extremely aggressive type of brain tumor showed promise in a pair of experiments with a handful of patients.
Scientists took patients’ own immune cells and turned them into “living drugs” able to recognize and attack glioblastoma. In the first-step tests, those cells shrank tumors at least temporarily, researchers reported Wednesday.
So-called CAR-T therapy already is used to fight blood-related cancers like leukemia but researchers have struggled to make it work for solid tumors. Now separate teams at Massachusetts General Hospital and the University of Pennsylvania are developing next-generation CAR-T versions designed to get past some of glioblastoma’s defenses.
“It’s very early days,” cautioned Penn’s Dr. Stephen Bagley, who led one of the studies. But “we’re optimistic that we’ve got something to build on here, a real foundation.”
Helicopter crashes in a field in New Hampshire, officials say
2025 Asian Winter Games to highlight environmental protection, technology
Retired Textile Worker Teaches Party's History
Guangzhou, Shanghai take lead in CBA playoffs
A fire at a Russian oil refinery has caused deaths and injuries, officials say
Liu Ying Conducts Scientific Research Like Running Marathon
Headmistress Committed to Primary School Education for Decades
Rural Delegate Wears Many Hats Serving Villagers
US dampens criticism of El Salvador's president as migration overtakes democracy concerns
Bringing History of Women Red Army Soldiers to Life